Trials / Completed
CompletedNCT00718887
Suboptimal Responders to Adefovir Switching to Entecavir
A Comparative Study of the Week 12 Antiviral Efficacy and Safety of Switching to Entecavir vs. Continuing Adefovir Treatment in Adults With Chronic Hepatitis B and Suboptimal Response to Adefovir
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 228 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
Switching to Entecavir will result in superior antiviral efficacy as compared to continuing with Adefovir in patients with a suboptimal response to Adefovir
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Entecavir | Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks |
| DRUG | Adefovir/Entecavir | Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2009-12-01
- Completion
- 2011-01-01
- First posted
- 2008-07-21
- Last updated
- 2013-02-11
- Results posted
- 2013-02-11
Locations
8 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00718887. Inclusion in this directory is not an endorsement.